← All trials
NCT04932265
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2021
- Primary completion
- Dec 31, 2021
- Completion date
- Jan 31, 2022
- First posted
- Jun 21, 2021
- Last posted
- Jun 21, 2021
- Enrollment
- 16
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- EuroPharma, Inc.Lead sponsor
- Government of ArmeniaCollaborator
- Government of ArmeniaOverall official - principal investigator
- Government of ArmeniaCollaborator
- Government of ArmeniaOverall official - principal investigator
- Institute of Fine Organic Chemistry of the National Academy of Science, ArmeniaStudy director
- Institute of Fine Organic Chemistry of the National Academy of Science Yerevan, ArmeniaCollaborator
- Phytomed ABCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.